Abstract
8058Background: IXA is an oral proteasome inhibitor recently approved for MM. Due to IXA’s Cytochrome P450 CYP3A4 and 1A2 metabolism, clinical trials of IXA excluded pts on 3A4 and 1A2 strong inhibitors and inducers. We examined the role of pharmacist review of potential drug-drug interactions (DDIs) in patients (pts) initiating IXA. Methods: Clinical trial pts receiving IXA between 1/2012 and 12/2015 for relapsed MM (NCT01415882; IXA, dexamethasone) and newly diagnosed MM (NCT01864018; IXA, dexamethasone, cyclophosphamide) were included. A pharmacist medication review for DDI was performed prior to IXA initiation. Baseline characteristics, concomitant medications, and toxicities were recorded. Results: Ninety-seven pts were included; 1 pt was excluded due to use of clarithromycin, a strong CYP3A4 inhibitor. Median age was 69 years (41-88) and 57% were male. The median number of concomitant medications was 9 (1-23). Four (4%) pts had potential CYP-mediated DDIs. One pt was on a strong CYP3A4 inducer (prim...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.